Latest Prostate Cancer News
Study of men who underwent salvage radical prostatectomy for radiorecurrent prostate cancer found a 10-year rate of biochemical progression-free survival of 33%.
Many patients with extraprostatic extension on biopsy experience biochemical recurrence after surgery and require early multi-modal therapy.
In a study, heart failure was nearly twice as likely to develop among ADT recipients compared with non-recipients.
Investigators conclude that microarray-generated cell cycle progression score should not be assumed to be a valid surrogate for qRT-PCR-generated scores.
As stearic acid and total fatty acid intake increased from one quintile to the next, prostate risk increased by 23% and 21%, respectively.
Patient selection and physician-patient commitment to careful follow-up surveillance are key.
Findings from a large contemporary cohort of men on active surveillance for prostate cancer shows that disease characteristics, not socioeconomic factors, are driving prostate cancer management.
Mistrust, lack of knowledge, unfavorable attitudes are barriers to genomic testing, study participation
New multidisciplinary guideline for early-stage prostate cancer developed by 3 professional societies.
The 3-year survival rate was 81% for patients who underwent EBRT plus standard care vs 73% for those who had standard care alone.
Trials show high survival rates, freedom from recurrence for low-, intermediate-risk prostate cancer.
Long-term data show a local disease recurrence rate of 2.1% at 10 years.
Among prostate cancer patients, androgen deprivation therapy (ADT) recipients are 34% more likely to experience any osteoporotic fracture than those who do not receive ADT.
New findings could help explain why men of African ancestry are more likely than white men to die from prostate cancer.
A midlife PSA value above the 90th percentile was associated with greater risk of total and aggressive prostate cancer in black men.
Sign up for free e-Newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)